Bronchodilator Drugs - Ukraine | Statista Market Forecast

In Ukraine, the revenue in the market of Bronchodilator Drugs market is forecasted to reach US$16.41m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 3.92%, leading to a market volume of US$19.89m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$17.34bn in 2024.
The demand for bronchodilator drugs in Ukraine has surged due to the high prevalence of respiratory diseases in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are an essential part of the pharmaceutical industry, with a growing demand worldwide. Ukraine is no exception to this trend, and the Bronchodilator Drugs market in Ukraine has been developing at a steady pace in recent years.

Customer preferences: The Bronchodilator Drugs market in Ukraine is driven by the increasing prevalence of respiratory diseases in the country. The demand for bronchodilator drugs has been rising due to the growing number of patients suffering from asthma, chronic obstructive pulmonary disease (COPD), and other respiratory illnesses. Patients prefer using bronchodilator drugs as they provide quick relief from breathing difficulties and are available in various forms such as inhalers, nebulizers, and tablets.

Trends in the market: The Bronchodilator Drugs market in Ukraine has witnessed significant growth in recent years, driven by the increasing prevalence of respiratory diseases in the country. The market is dominated by a few major players, and the competition among them is intense. The trend of using combination therapies for treating respiratory diseases is gaining popularity in Ukraine. Combination therapy involves the use of two or more drugs to achieve better results in treating respiratory diseases. The demand for combination therapies is increasing as they provide better control over respiratory symptoms and improve patient outcomes.

Local special circumstances: The Ukrainian government has been taking steps to improve the healthcare system in the country, which has led to an increase in the availability of healthcare services. The government has also been promoting the use of generic drugs to reduce the cost of healthcare services. This has led to an increase in the use of generic bronchodilator drugs in the country. However, the quality of generic drugs has been a concern, and the government has been taking steps to improve the quality of generic drugs in the country.

Underlying macroeconomic factors: The Ukrainian economy has been recovering from the economic crisis that hit the country in 2014. The pharmaceutical industry has been one of the key sectors driving the economic growth in the country. The government has been providing incentives to the pharmaceutical industry to encourage the production of essential drugs in the country. The increasing demand for bronchodilator drugs in Ukraine has led to an increase in the production of these drugs in the country. The availability of locally produced bronchodilator drugs has led to a reduction in the cost of these drugs, making them more affordable for patients.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.